Effects of DGAT1 deficiency on energy and glucose metabolism are independent of adiponectin

RS Streeper, SK Koliwad… - American Journal of …, 2006 - journals.physiology.org
American Journal of Physiology-Endocrinology and Metabolism, 2006journals.physiology.org
Mice lacking acyl-CoA: diacylglycerol acyltransferase 1 (DGAT1), an enzyme that catalyzes
the terminal step in triacylglycerol synthesis, have enhanced insulin sensitivity and are
protected from obesity, a result of increased energy expenditure. In these mice, factors
derived from white adipose tissue (WAT) contribute to the systemic changes in metabolism.
One such factor, adiponectin, increases fatty acid oxidation and enhances insulin sensitivity.
To test the hypothesis that adiponectin is required for the altered energy and glucose …
Mice lacking acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1), an enzyme that catalyzes the terminal step in triacylglycerol synthesis, have enhanced insulin sensitivity and are protected from obesity, a result of increased energy expenditure. In these mice, factors derived from white adipose tissue (WAT) contribute to the systemic changes in metabolism. One such factor, adiponectin, increases fatty acid oxidation and enhances insulin sensitivity. To test the hypothesis that adiponectin is required for the altered energy and glucose metabolism in DGAT1-deficient mice, we generated adiponectin-deficient mice and introduced adiponectin deficiency into DGAT1-deficient mice by genetic crosses. Although adiponectin-deficient mice fed a high-fat diet were heavier, exhibited worse glucose tolerance, and had more hepatic triacylglycerol accumulation than wild-type controls, mice lacking both DGAT1 and adiponectin, like DGAT1-deficient mice, were protected from diet-induced obesity, glucose intolerance, and hepatic steatosis. These findings indicate that adiponectin is required for normal energy, glucose, and lipid metabolism but that the metabolic changes induced by DGAT1-deficient WAT are independent of adiponectin and are likely due to other WAT-derived factors. Our findings also suggest that the pharmacological inhibition of DGAT1 may be useful for treating human obesity and insulin resistance associated with low circulating adiponectin levels.
American Physiological Society